CDKN2A and neoplasm: Additionally, stratified survival analysis suggested that CDKN2A-ALT patients were shorter OS than CDKN2A-WT patients across multiple levels of CNA, MSI, TMB, age, mutation count, gender, tumor purity and race (Figure S1H).